Interestingly, the SMARCB1/INI1-/p53+ group (8% of cases, 11/134 patients) showed a very short OS in all tumor stages I-IV or stages I-II alone, when compared to any other SMARCB1/INI1/p53 combination (Figure 4B,C). Here, SMARCB1 is linked to neoplasm.